- PR Newswire•19 days agoPeople with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima® (lenvatinib) in Scotland
HATFIELD, England, October 10, 2016 /PRNewswire/ -- Patients in England denied access to lenvatinib due to administrative delays The Scottish Medicines Consortium (SMC) approves the use of Lenvima ® ...
- PR Newswire•2 months agoEisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven® (eribulin) in the Treatment of Advanced Liposarcoma
HATFIELD, England, September 4, 2016 /PRNewswire/ -- FOR EMEA MEDIA ONLY: NOT FOR SWISS/AUSTRIAN JOURNALISTS Assessment ignores unprecedented overall survival benefit for eribulin in advanced ...
- Capital Cube•2 months ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Eisai Co., Ltd. Here are 5 ETF’s with the largest exposure to ESALY-US. Comparing the performance and risk of Eisai Co., Ltd. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Eisai Co., Ltd. (ESALY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||65.36 - 65.36|
|52wk Range||53.55 - 66.38|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.12|
|Avg Vol (3m)||2,078|
|Dividend & Yield||1.46 (2.23%)|